Compare SBUX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBUX | BMY |
|---|---|---|
| Founded | 1971 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7B | 123.7B |
| IPO Year | 1994 | N/A |
| Metric | SBUX | BMY |
|---|---|---|
| Price | $99.09 | $59.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 15 |
| Target Price | ★ $100.84 | $61.93 |
| AVG Volume (30 Days) | 6.9M | ★ 9.8M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 2.48% | ★ 4.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $37,184,400,000.00 | N/A |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $384.62 | ★ $17.26 |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $75.50 | $42.52 |
| 52 Week High | $104.82 | $62.89 |
| Indicator | SBUX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.86 | 45.35 |
| Support Level | $82.38 | $53.88 |
| Resistance Level | $99.41 | $62.47 |
| Average True Range (ATR) | 2.36 | 1.16 |
| MACD | 0.08 | -0.51 |
| Stochastic Oscillator | 62.46 | 13.25 |
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.